ArticleNPJ digital medicine2026
Telemonitoring modalities in heart failure: comparative effectiveness across the heart failure population-a meta-analysis.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Remote monitoring (RM) is effective for managing heart failure (HF), but it remains unclear which patients benefit most from which RM modality. We conducted a meta-analysis of 79 randomised trials including 31,669 patients comparing RM with standard care for total and first HF hospitalisations and all-cause mortality. Subgroup analyses evaluated effects by geographic region and HF status, and meta-regression assessed the influence of age, left ventricular ejection fraction, New York Heart Association class, sex, and publication year. Network meta-analysis ranked RM modalities using Surface Under the Cumulative Ranking scores. Overall, RM reduced total HF hospitalisations (incidence rate ratio 0.81, 95% confidence interval [CI] 0.72-0.91), first HF hospitalisations (risk ratio 0.82, 95% CI: 0.76-0.88), and all-cause mortality (risk ratio 0.90, 95% CI: 0.84-0.95). Subgroup and meta-regression analyses showed consistent benefits across patient and study characteristics without significant interaction effects. In network meta-analysis, invasive hemodynamic monitoring ranked highest for reducing total HF hospitalisations, while structured telephone support ranked highest for reducing first HF hospitalisation and all-cause mortality. RM consistently improves HF outcomes across a range of patient and study characteristics, supporting its broad use. However, based on these characteristics, current evidence does not allow targeted RM implementation for specific patients most likely to benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.